$DVAX
DYNAVAX TECHNOLOGIES CORP

2024 Q3 Form 10-Q Financial Statement

#000095017024091804 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $80.63M $73.80M
YoY Change 15.99% 22.48%
Cost Of Revenue $13.08M $11.99M
YoY Change -0.88% -11.46%
Gross Profit $67.55M $61.81M
YoY Change 19.98% 32.32%
Gross Profit Margin 83.77% 83.76%
Selling, General & Admin $43.06M $41.66M
YoY Change 13.16% 12.38%
% of Gross Profit 63.75% 67.4%
Research & Development $14.40M $14.95M
YoY Change 2.03% 14.59%
% of Gross Profit 21.32% 24.19%
Depreciation & Amortization $1.184M $1.135M
YoY Change 7.64% 3.18%
% of Gross Profit 1.75% 1.84%
Operating Expenses $57.46M $56.61M
YoY Change 10.15% 12.96%
Operating Profit $10.08M $5.198M
YoY Change 97.07% -252.66%
Interest Expense $7.683M $1.698M
YoY Change 354.35% 0.59%
% of Operating Profit 76.21% 32.67%
Other Income/Expense, Net -$152.0K $0.00
YoY Change -157.14% -100.0%
Pretax Income $19.82M $14.91M
YoY Change 40.1% 254.31%
Income Tax $2.200M $3.500M
% Of Pretax Income 11.1% 23.48%
Net Earnings $17.59M $11.39M
YoY Change 23.1% 231.86%
Net Earnings / Revenue 21.82% 15.43%
Basic Earnings Per Share $0.13 $0.09
Diluted Earnings Per Share $0.12 $0.08
COMMON SHARES
Basic Shares Outstanding 131.0M 130.9M
Diluted Shares Outstanding 154.8M shares 154.5M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $764.0M $735.6M
YoY Change 6.05% 7.94%
Cash & Equivalents $119.3M $112.5M
Short-Term Investments $644.7M $623.1M
Other Short-Term Assets $24.57M $21.31M
YoY Change 29.32% 21.8%
Inventory $62.40M $62.46M
Prepaid Expenses
Receivables $73.33M $61.65M
Other Receivables $1.943M $976.0K
Total Short-Term Assets $926.2M $882.0M
YoY Change 10.84% 10.6%
LONG-TERM ASSETS
Property, Plant & Equipment $37.42M $36.11M
YoY Change 3.42% -3.57%
Goodwill $2.091M $2.007M
YoY Change 5.55% -1.57%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $74.46M $73.67M
YoY Change 0.41% -0.33%
Total Long-Term Assets $135.7M $134.3M
YoY Change -1.11% -3.36%
TOTAL ASSETS
Total Short-Term Assets $926.2M $882.0M
Total Long-Term Assets $135.7M $134.3M
Total Assets $1.062B $1.016B
YoY Change 9.15% 8.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.089M $4.555M
YoY Change 127.21% 40.33%
Accrued Expenses $54.10M $48.49M
YoY Change 24.48% 43.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $70.03M $62.19M
YoY Change 29.05% 38.63%
LONG-TERM LIABILITIES
Long-Term Debt $223.6M $223.3M
YoY Change 0.52% 0.51%
Other Long-Term Liabilities $28.00K $198.0K
YoY Change -91.28% -43.27%
Total Long-Term Liabilities $28.00K $198.0K
YoY Change -91.28% -43.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.03M $62.19M
Total Long-Term Liabilities $28.00K $198.0K
Total Liabilities $380.6M $373.5M
YoY Change 3.41% 3.97%
SHAREHOLDERS EQUITY
Retained Earnings -$910.3M -$927.9M
YoY Change -2.2% -1.82%
Common Stock $1.591B $1.576B
YoY Change 3.21% 3.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $681.4M $642.8M
YoY Change
Total Liabilities & Shareholders Equity $1.062B $1.016B
YoY Change 9.15% 8.53%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $17.59M $11.39M
YoY Change 23.1% 231.86%
Depreciation, Depletion And Amortization $1.184M $1.135M
YoY Change 7.64% 3.18%
Cash From Operating Activities $19.47M $10.71M
YoY Change -37.41% -61.8%
INVESTING ACTIVITIES
Capital Expenditures $1.346M $779.0K
YoY Change 236.5% 3.73%
Acquisitions
YoY Change
Other Investing Activities -$14.12M -$27.99M
YoY Change -86.64% -209.87%
Cash From Investing Activities -$15.47M -$28.77M
YoY Change -85.42% -216.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.476M -1.415M
YoY Change -17.47% 381.29%
NET CHANGE
Cash From Operating Activities 19.47M 10.71M
Cash From Investing Activities -15.47M -28.77M
Cash From Financing Activities 2.476M -1.415M
Net Change In Cash 6.478M -19.47M
YoY Change -109.0% -137.1%
FREE CASH FLOW
Cash From Operating Activities $19.47M $10.71M
Capital Expenditures $1.346M $779.0K
Free Cash Flow $18.12M $9.934M
YoY Change -40.97% -63.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112771000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
227033000
us-gaap Income Taxes Paid
IncomeTaxesPaid
2963000
us-gaap Income Taxes Paid
IncomeTaxesPaid
710000
us-gaap Interest Paid Net
InterestPaidNet
2819000
us-gaap Interest Paid Net
InterestPaidNet
2819000
dvax Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
0
dvax Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
71307000
dvax Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
0
dvax Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
-60337000
CY2024Q2 dvax Advance Payment From Customer
AdvancePaymentFromCustomer
0
CY2023Q2 dvax Advance Payment From Customer
AdvancePaymentFromCustomer
-47401000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
574000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
540000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
901000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">informed estimates and assumptions that may affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes, including amounts of revenues and expenses during the reported periods. Management’s estimates are based on historical information available as of the date of the unaudited condensed consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. On an ongoing basis, we evaluate our estimates, judgments and methodologies. Significant estimates and assumptions in the unaudited condensed consolidated financial statements include those related to revenue recognition; accounts receivable; useful lives of long-lived assets; valuation procedures for right-of-use assets and operating lease liabilities; valuation of inventory; research and development expenses; contingencies and share-based compensation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
dei Entity Central Index Key
EntityCentralIndexKey
0001029142
CY2024Q2 ecd Trd Arr Duration
TrdArrDuration
P471D
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34207
dei Entity Registrant Name
EntityRegistrantName
Dynavax Technologies Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0728374
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 Powell Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 720
dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
848-5100
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
DVAX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131044383
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112501000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150279000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
623111000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
592023000
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12313000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12313000
CY2024Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
61654000
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
40607000
CY2024Q2 us-gaap Other Receivables
OtherReceivables
976000
CY2023Q4 us-gaap Other Receivables
OtherReceivables
3926000
CY2024Q2 us-gaap Inventory Net
InventoryNet
62462000
CY2023Q4 us-gaap Inventory Net
InventoryNet
53290000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21308000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18995000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
882012000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
859120000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36105000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37297000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22526000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24287000
CY2024Q2 us-gaap Goodwill
Goodwill
2007000
CY2023Q4 us-gaap Goodwill
Goodwill
2067000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
73671000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
74325000
CY2024Q2 us-gaap Assets
Assets
1016321000
CY2023Q4 us-gaap Assets
Assets
997096000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4555000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5245000
CY2024Q2 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4581000
CY2023Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2982000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
48488000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49448000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4568000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4520000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
62192000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62195000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2228000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2802000
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
223272000
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
222698000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27473000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29720000
CY2024Q2 dvax Cepi Accrual Long Term
CepiAccrualLongTerm
60337000
CY2023Q4 dvax Cepi Accrual Long Term
CepiAccrualLongTerm
60337000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
198000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
74000
CY2024Q2 us-gaap Liabilities
Liabilities
373472000
CY2023Q4 us-gaap Liabilities
Liabilities
375024000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
130984000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130984000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
129530000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
129530000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
131000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
130000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1575548000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1554634000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4911000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2108000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-927919000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-930584000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
642849000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
622072000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1016321000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
997096000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73795000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60249000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
124584000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107174000
CY2024Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
11985000
CY2023Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
13537000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
22952000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
28249000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14950000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13046000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28478000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26651000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
41662000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37071000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
85727000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
73614000
CY2024Q2 dvax Bad Debt Expense
BadDebtExpense
0
CY2023Q2 dvax Bad Debt Expense
BadDebtExpense
0
dvax Bad Debt Expense
BadDebtExpense
0
dvax Bad Debt Expense
BadDebtExpense
12313000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
68597000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
63654000
us-gaap Costs And Expenses
CostsAndExpenses
137157000
us-gaap Costs And Expenses
CostsAndExpenses
140827000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
5198000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3405000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12573000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33653000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
9201000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
7378000
us-gaap Investment Income Interest
InvestmentIncomeInterest
18668000
us-gaap Investment Income Interest
InvestmentIncomeInterest
13975000
CY2024Q2 us-gaap Interest Expense
InterestExpense
1698000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1688000
us-gaap Interest Expense
InterestExpense
3393000
us-gaap Interest Expense
InterestExpense
3374000
CY2024Q2 dvax Sublease Expense Income
SubleaseExpenseIncome
2205000
CY2023Q2 dvax Sublease Expense Income
SubleaseExpenseIncome
1993000
dvax Sublease Expense Income
SubleaseExpenseIncome
603000
dvax Sublease Expense Income
SubleaseExpenseIncome
3591000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-71000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
103000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14906000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4207000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3408000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19509000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3520000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
776000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
743000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1392000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
11386000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
3431000
us-gaap Net Income Loss
NetIncomeLoss
2665000
us-gaap Net Income Loss
NetIncomeLoss
-20901000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130916000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128625000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130551000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128275000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154468000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152142000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
133582000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128275000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
11386000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
3431000
us-gaap Net Income Loss
NetIncomeLoss
2665000
us-gaap Net Income Loss
NetIncomeLoss
-20901000
CY2024Q2 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-289000
CY2023Q2 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-1197000
dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-1746000
dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-531000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-249000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
25000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1057000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112501000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150279000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
226823000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
202004000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
270000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
277000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
210000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
207000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112771000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150556000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
227033000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202211000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
372276000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
371881000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
251736000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
251230000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
597000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-538000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1172000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2803000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
66000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
10848000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2259000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-138000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20835000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
618480000
CY2024Q2 dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
419000
CY2024Q2 dvax Issuance Of Common Stock Upon Release Of Restricted Stock Awards Net Of Statutory Tax Withholdings
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
-416000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13518000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-538000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
11386000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
642849000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
622072000
dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
2054000
dvax Issuance Of Common Stock Upon Release Of Restricted Stock Awards Net Of Statutory Tax Withholdings
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
-8575000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
904000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26532000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2803000
us-gaap Net Income Loss
NetIncomeLoss
2665000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
642849000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
563732000
CY2023Q2 dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
1378000
CY2023Q2 dvax Issuance Of Common Stock Upon Release Of Restricted Stock Awards Net Of Statutory Tax Withholdings
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
-726000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10562000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1172000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
3431000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
577205000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
581013000
dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
1617000
dvax Issuance Of Common Stock Upon Release Of Restricted Stock Awards Net Of Statutory Tax Withholdings
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
-5963000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
777000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20596000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
66000
us-gaap Net Income Loss
NetIncomeLoss
-20901000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
577205000
us-gaap Net Income Loss
NetIncomeLoss
2665000
us-gaap Net Income Loss
NetIncomeLoss
-20901000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2259000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2113000
dvax Amortization Of Right Of Use Assets And Loss On Disposal Of Property And Equipment
AmortizationOfRightOfUseAssetsAndLossOnDisposalOfPropertyAndEquipment
1668000
dvax Amortization Of Right Of Use Assets And Loss On Disposal Of Property And Equipment
AmortizationOfRightOfUseAssetsAndLossOnDisposalOfPropertyAndEquipment
1335000
us-gaap Inventory Write Down
InventoryWriteDown
1264000
us-gaap Inventory Write Down
InventoryWriteDown
0
dvax Sublease Loss
SubleaseLoss
4765000
dvax Sublease Loss
SubleaseLoss
0
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
8465000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
7263000
us-gaap Share Based Compensation
ShareBasedCompensation
26532000
us-gaap Share Based Compensation
ShareBasedCompensation
20596000
dvax Bad Debt Expense
BadDebtExpense
0
dvax Bad Debt Expense
BadDebtExpense
12313000
dvax Non Cash Interest Expense
NonCashInterestExpense
574000
dvax Non Cash Interest Expense
NonCashInterestExpense
556000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
18097000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-42448000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
10436000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-6358000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6290000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3172000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
101000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-703000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-569000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-151000
dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
2109000
dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
1679000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
374000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2412000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5966000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
55668000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
326121000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
259531000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
301713000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
233953000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1528000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2034000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25936000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27612000
dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
2054000
dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
1617000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
904000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
777000
dvax Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
8576000
dvax Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
5778000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5618000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3384000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-265000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37785000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24822000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150556000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202211000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
624012000
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
623111000
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
24130000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
27256000
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
23011000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
18954000
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
15321000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7080000
CY2024Q2 us-gaap Inventory Net
InventoryNet
62462000
CY2023Q4 us-gaap Inventory Net
InventoryNet
53290000
CY2024Q1 dvax Opearting Lease Rent Area
OpeartingLeaseRentArea
75662
CY2024Q1 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
3500000
CY2024Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
4800000
CY2024Q1 dvax Collection Of Termination Payment
CollectionOfTerminationPayment
1300000
us-gaap Sublease Income
SubleaseIncome
2200000
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
600000
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
2000000
us-gaap Sublease Income
SubleaseIncome
3600000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1496000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1392000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2912000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2780000
us-gaap Operating Lease Payments
OperatingLeasePayments
3800000
us-gaap Operating Lease Payments
OperatingLeasePayments
3500000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4536000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4496000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27473000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29720000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
32009000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
34216000
CY2024Q2 dvax Lessor Sublease Rentals Payments To Be Received Remainder Of Fiscal Year
LessorSubleaseRentalsPaymentsToBeReceivedRemainderOfFiscalYear
2960000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3808000
CY2024Q2 dvax Lessor Sublease Rentals Payments To Be Received Due Year Two
LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo
6127000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6962000
CY2024Q2 dvax Lessor Sublease Rentals Payments To Be Received Due Year Three
LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree
6342000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6103000
CY2024Q2 dvax Lessor Sublease Rentals Payments To Be Received Due Year Four
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour
6564000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6034000
CY2024Q2 dvax Lessor Sublease Rentals Payments To Be Received Due Year Five
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive
6794000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6197000
CY2024Q2 dvax Lessor Sublease Rentals Payments To Be Received Due Thereafter
LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter
16191000
CY2024Q2 dvax Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
15007000
CY2024Q2 dvax Lessor Sublease Rentals Payments To Be Received
LessorSubleaseRentalsPaymentsToBeReceived
44978000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
44111000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12102000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
32009000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y4M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
dvax Description Of Avecia Supply Agreement
DescriptionOfAveciaSupplyAgreement
On September 7, 2023 (the “Effective Date”), we entered into an agreement (the “Avecia Supply Agreement”) with Nitto Denko Avecia Inc. (“Avecia”) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the “2012 Agreement”). Included in the balance of our material non-cancelable purchase and other commitments for the supply of HEPLISAV-B, as of June 30, 2024 and December 31, 2023, our aggregate minimum commitment for the supply of CpG 1018 adjuvant under the Avecia Supply Agreement totaled $7.4 million for each period, anticipated within the next 12 months.
CY2024Q2 dvax Aggregate Minimum Commitment
AggregateMinimumCommitment
7400000
CY2023Q4 dvax Aggregate Minimum Commitment
AggregateMinimumCommitment
7400000
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12300000
CY2023Q2 dvax Prepayment Of Advance Payment
PrepaymentOfAdvancePayment
13500000
CY2023Q2 dvax Repayment Of Advance From Customer
RepaymentOfAdvanceFromCustomer
47400000
us-gaap Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
38700
us-gaap Debt Instrument Convertible Threshold Trading Days
DebtInstrumentConvertibleThresholdTradingDays
20
CY2024Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
280000000
CY2024Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1409000
CY2023Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1409000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2818000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2818000
CY2024Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
289000
CY2023Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
279000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
575000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
556000
CY2024Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
1698000
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
1688000
us-gaap Interest Expense Debt
InterestExpenseDebt
3393000
us-gaap Interest Expense Debt
InterestExpenseDebt
3374000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73795000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
60249000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
124584000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107174000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
11386000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
3431000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2665000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20901000
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1273000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1266000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
12659000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
4697000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
2665000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20901000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130916000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128625000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130551000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128275000
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2009000
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1974000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3031000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2024Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
21543000
CY2023Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
21543000
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154468000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152142000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
133582000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128275000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8891000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6900000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28509000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37075000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130984369
CY2024Q2 dvax Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance
IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance
11400000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10120000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.78
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M4D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37388000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1685000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.39
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
316000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
144000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
14.63
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11343000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.07
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M19D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14929000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11141000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
11.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y2M1D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
14923000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8118000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.65
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y6M3D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14696000
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
13518000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
10562000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
26532000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
20596000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3500000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
700000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1400000
CY2024Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.236
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.218
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.031
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.057
CY2024Q2 ecd Trd Arr Ind Name
TrdArrIndName
Robert Janssen
CY2024Q2 ecd Trd Arr Ind Title
TrdArrIndTitle
M.D.,Chief Medical Officer and Senior Vice President
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2024Q2 ecd Trd Arr Adoption Date
TrdArrAdoptionDate
May 30, 2024
CY2024Q2 ecd Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
311535
CY2024Q2 ecd Trd Arr Expiration Date
TrdArrExpirationDate
September 12, 2025

Files In Submission

Name View Source Status
0000950170-24-091804-index-headers.html Edgar Link pending
0000950170-24-091804-index.html Edgar Link pending
0000950170-24-091804.txt Edgar Link pending
0000950170-24-091804-xbrl.zip Edgar Link pending
dvax-20240630.htm Edgar Link pending
dvax-20240630.xsd Edgar Link pending
dvax-ex10_1.htm Edgar Link pending
dvax-ex10_2.htm Edgar Link pending
dvax-ex31_1.htm Edgar Link pending
dvax-ex31_2.htm Edgar Link pending
dvax-ex32_1.htm Edgar Link pending
dvax-20240630_htm.xml Edgar Link completed
dvax-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable